Cargando…
Antibody therapy reverses biological signatures of COVID-19 progression
Understanding who is at risk of progression to severe coronavirus disease 2019 (COVID-19) is key to clinical decision making and effective treatment. We study correlates of disease severity in the COMET-ICE clinical trial that randomized 1:1 to placebo or to sotrovimab, a monoclonal antibody for the...
Autores principales: | Maher, M. Cyrus, Soriaga, Leah B., Gupta, Anil, Chen, Yi-Pei, di Iulio, Julia, Ledoux, Sarah, Smithey, Megan J., Cathcart, Andrea L., McKusick, Kathleen, Sun, David, Aldinger, Melissa, Alexander, Elizabeth, Purcell, Lisa, Ding, Xiao, Peppercorn, Amanda, Austin, Daren, Mogalian, Erik, Yeh, Wendy W., Shapiro, Adrienne E., Corti, Davide, Virgin, Herbert W., Pang, Phillip S., Telenti, Amalio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380250/ https://www.ncbi.nlm.nih.gov/pubmed/35977462 http://dx.doi.org/10.1016/j.xcrm.2022.100721 |
Ejemplares similares
-
Advances in Genomics for Drug Development
por: Spreafico, Roberto, et al.
Publicado: (2020) -
Predicting the mutational drivers of future SARS-CoV-2 variants of concern
por: Maher, M. Cyrus, et al.
Publicado: (2022) -
Transfer transcriptomic signatures for infectious diseases
por: di Iulio, Julia, et al.
Publicado: (2021) -
502. Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab
por: Gupta, Anil K, et al.
Publicado: (2021) -
1150. Resistance Analysis in the COMET-TAIL Study: Participants with Mild-to-Moderate COVID-19 Treated with Intramuscular or Intravenous Sotrovimab
por: Agostini, Maria L, et al.
Publicado: (2022)